Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series
暂无分享,去创建一个
K. S. Hall | Robin L. Jones | J. Blay | L. Mariani | O. Mir | A. D. Dei Tos | P. Rutkowski | R. Benjamin | P. Casali | A. Fedenko | H. Gelderblom | A. Gronchi | K. Hall | P. Picci | S. Stacchiotti | B. Vincenzi | J. Hornick | S. Lo Vullo | K. Thway | A. Frezza | J. Broto | G. Grignani | I. Lobmaier | P. Collini | A. Brunello | E. Palmerini | A. Kawai | M. Brahmi | A. Yoshida | K. Boye | M. Sbaraglia | S. L. Renne | I. Desar | R. Ratan | N. Asano | O. Anurova | U. Flucke | D. Ranchère | A. Wagner | E. Ben-Ami | M. Wągrodzki | P. Teterycz | F. Lucibello | T. Philippe | Wei-Lien Wang | S. Renne
[1] P. Casali,et al. 1486PAn epidemiological insight into epithelioid sarcoma (ES): The open issue of distal-type (DES) versus proximal-type (PES) , 2017 .
[2] Robin L. Jones,et al. Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950). , 2017 .
[3] P. Terrier,et al. Vinorelbine-based chemotherapy in metastatic epithelioid sarcoma. , 2016 .
[4] K. Horiuchi,et al. Successful Treatment with Pazopanib for Multiple Lung Metastases of Inguinal Epithelioid Sarcoma: A Case Report , 2015, Case Reports in Oncology.
[5] A. Kawai,et al. Prognostic Value of Relevant Clinicopathologic Variables in Epithelioid Sarcoma: A Multi-Institutional Retrospective Study of 44 Patients , 2015, Annals of Surgical Oncology.
[6] P. Reichardt,et al. Gemcitabine and Docetaxel for Epithelioid Sarcoma: Results from a Retrospective, Multi-Institutional Analysis , 2014, Oncology.
[7] A. D. Dei Tos,et al. SMARCB1/INI1 Genetic Inactivation Is Responsible for Tumorigenic Properties of Epithelioid Sarcoma Cell Line VAESBJ , 2013, Molecular Cancer Therapeutics.
[8] C. Fletcher,et al. WHO classification of tumours of soft tissue and bone , 2013 .
[9] Robin L. Jones,et al. Role of Palliative Chemotherapy in Advanced Epithelioid Sarcoma , 2012, American journal of clinical oncology.
[10] P. D. Dal Cin,et al. Loss of INI1 Expression is Characteristic of Both Conventional and Proximal-type Epithelioid Sarcoma , 2009, The American journal of surgical pathology.
[11] S. Scully,et al. Prognostic Factors for Survival in Patients with Epithelioid Sarcoma: 441 Cases from the SEER Database , 2009, Clinical orthopaedics and related research.
[12] F. Collin,et al. A Clinicopathologic and Immunohistochemical Analysis of 106 Cases From the French Sarcoma Group , 2009 .
[13] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[14] D. Harms,et al. Epithelioid sarcoma in children and adolescents , 2004, Virchows Archiv A.
[15] S. Hirohashi,et al. Proximal-Type Epithelioid Sarcoma: A Clinicopathologic Study of 20 Cases , 2001, Modern Pathology.
[16] H. Lynch,et al. Psychologic Aspects of Cancer Genetic Testing: A Research Update for Clinicians , 1997 .